These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 26586796)

  • 1. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.
    Iacovazzo D; Carlsen E; Lugli F; Chiloiro S; Piacentini S; Bianchi A; Giampietro A; Mormando M; Clear AJ; Doglietto F; Anile C; Maira G; Lauriola L; Rindi G; Roncaroli F; Pontecorvi A; Korbonits M; De Marinis L
    Eur J Endocrinol; 2016 Feb; 174(2):241-50. PubMed ID: 26586796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
    Muhammad A; Coopmans EC; Gatto F; Franck SE; Janssen JAMJL; van der Lely AJ; Hofland LJ; Neggers SJCMM
    J Clin Endocrinol Metab; 2019 Mar; 104(3):915-924. PubMed ID: 30346538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
    Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
    Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pasireotide in the Personalized Treatment of Acromegaly.
    Puig-Domingo M; Bernabéu I; Picó A; Biagetti B; Gil J; Alvarez-Escolá C; Jordà M; Marques-Pamies M; Soldevila B; Gálvez MA; Cámara R; Aller J; Lamas C; Marazuela M
    Front Endocrinol (Lausanne); 2021; 12():648411. PubMed ID: 33796079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.
    Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C
    Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
    Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
    Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
    Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
    Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
    Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
    Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study.
    Chiloiro S; Bima C; Tartaglione T; Giampietro A; Gessi M; Lauretti L; Anile C; Colosimo C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5478-5482. PubMed ID: 31219586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly.
    Gatto F; Biermasz NR; Feelders RA; Kros JM; Dogan F; van der Lely AJ; Neggers SJ; Lamberts SW; Pereira AM; Ferone D; Hofland LJ
    Eur J Endocrinol; 2016 May; 174(5):651-62. PubMed ID: 26888629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.
    Chiloiro S; Giampietro A; Mirra F; Donfrancesco F; Tartaglione T; Mattogno PP; Angelini F; Liverana L; Gessi M; Carmelo A; Rindi G; Giustina A; Fleseriu M; Pontecorvi A; De Marinis L; Bianchi A
    Eur J Endocrinol; 2021 Feb; 184(2):217-229. PubMed ID: 33136550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.
    Coopmans EC; Schneiders JJ; El-Sayed N; Erler NS; Hofland LJ; van der Lely AJ; Petrossians P; Potorac J; Muhammad A; Neggers SJCMM
    Eur J Endocrinol; 2020 Jun; 182(6):595-605. PubMed ID: 32375119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
    Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
    Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
    Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly.
    Venegas-Moreno E; Vazquez-Borrego MC; Dios E; Gros-Herguido N; Flores-Martinez A; Rivero-Cortés E; Madrazo-Atutxa A; Japón MA; Luque RM; Castaño JP; Cano DA; Soto-Moreno A
    J Cell Mol Med; 2018 Mar; 22(3):1640-1649. PubMed ID: 29266696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
    Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
    BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary.
    Lee M; Lupp A; Mendoza N; Martin N; Beschorner R; Honegger J; Schlegel J; Shively T; Pulz E; Schulz S; Roncaroli F; Pellegata NS
    Endocr Relat Cancer; 2015 Feb; 22(1):111-9. PubMed ID: 25515731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide.
    Casar-Borota O; Heck A; Schulz S; Nesland JM; Ramm-Pettersen J; Lekva T; Alafuzoff I; Bollerslev J
    J Clin Endocrinol Metab; 2013 Nov; 98(11):E1730-9. PubMed ID: 24092823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
    Rass L; Rahvar AH; Matschke J; Saeger W; Renné T; Aberle J; Flitsch J; Rotermund R
    Hormones (Athens); 2022 Mar; 21(1):79-89. PubMed ID: 34674191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.